Authorities in Zhejiang, China granted Jiangsu Sinopep-Allsino Biopharmaceutical (SHA:688076) a good manufacturing practice certification for its Olgotrelvir Sodium raw material, according to a Wednesday filing with the Shanghai bourse.
Sinopep subsidiary Hangzhou Ausino Biotechnology produced the formulation, the filing said.
The drug is being used as a standalone drug for COVID-19, the National Institutes for Public Health said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.